HDAC11-IN-3

Overview

HDAC11-IN-3 (Compound A9) is a selective HDAC11 inhibitor ( IC 50 : 4.1 nM). HDAC11-IN-3 has inhibitory effects on U937 and OCI-AML2 acute myeloid leukemia (AML) cell lines ( IC 50 : 10 μM). HDAC11-IN-3 has significant anti-AML activity, inducing apoptosis , cell cycle arrest, and differentiation. HDAC11-IN-3 upregulates the iron transporters transferrin ( TF ) and transferrin receptor ( TFRC ), and activates the p62-Keap1-Nrf2-HMOX1 pathway, which together lead to increased intracellular iron levels and induce ferroptosis in AML cells. HDAC11-IN-3 can be used alone or in combination with Cytarabine ( HY-13605 ) for AML research.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HDAC | Products > Signaling Pathways > Transferrin Receptor | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Ferroptosis

Product Information

• Catalog No.: HY-173444
• CAS No.: 2989934-63-4
• Molecular Formula: C18H11F3N2O2
• Molecular Weight: 344.29
• Purity: 99.70%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Availability: In-stock

Source

Original product source